

CURRICULUM VITAE

JEFFREY R. IDLE

Internationally renowned researcher in metabolism and metabolomics with a strong background in biochemistry and analytical chemistry. Discoverer of the first genetic polymorphism in cytochrome P450 with a significant impact on drug and environmental chemical metabolism. Metabolites form the bond between

4. Journal editorial boards and reviewing

Biochemical Pharmacology (2022 IF = 6.1) – Editorial Board member (2010-present)

In addition, currently *ad hoc* reviewer for *ACS Books*, *Am J Primatol*, *Animal Biol*, *Annals of Medicine*, *BBA Clin*, *Carcinogenesis*, *Clin Cancer Res*, *Curr Pharmacol Rep*, *Drug Metab Dispos*, *Drug Metab Rev*, *DNA Repair*, *Hepatology*, *Internat J Radiat Biol*, *J Chromatogr B*, *J Hepatol*, *J*

peripheral or bone marrow blasts and an unfavorable prognostic risk. Conversely, plasma PGF2 . was predominantly elevated in AML patients with low peripheral or bone marrow blasts and with a favorable prognostic risk. These and other findings in this report (Pabst *et al.*, 2017) are leading to novel insights into the pathobiology of AML.

In summary, my research experience over four decades can best be described as multidisciplinary translational research in the field of cancer and preneoplastic disease. There has been a significant focus on cancer etiology, specifically, *CYP2D6* as the first susceptibility gene for lung cancer (Ayesh *et al.*, 1984; Caporaso *et al.*, 1989a,b; Law *et al.*, 1989), *GSTM1* in bladder cancer (Daly *et al.*, 1993) and *CYP2D6* in breast cancer (Pontin *et al.*, 1990). Moreover, we have applied metabolomics to the discovery of cancer biomarkers and improved insights into cancer mechanisms. Examples include hepatocellular carcinoma (Patterson *et al.*, 2011; Beyo ~~fu~~ *et al.*, 2013), lung cancer (Mathé *et al.*, 2014), acute myeloid leukemia (Pabst *et al.*, 2017), lipidome reprogramming in relation to the murine tumor suppressor gene *Hint1* (Beyo ~~fu~~ *et al*

f. Long Island University Brooklyn

2020-2022 California Table Grape Commission	\$89,000
2022 (pending) Ambys Medicines	\$278,769

I therefore have a record of competitive grant funding in several different countries.

Balthazar Schmid, PhD	(CH)	London	1982-84 Pharmacy owner, Luzern, Switzerland
Nicholas S. Oates, PhD	(UK)	London	1983-85 ? London

is now Pro-Vice-Chancellor for Learning and Teaching, the other, a professor of pharmacogenetics. This shows clear evidence of mentoring junior staff.

- (iii) Establishment *ab initio* of the Department of Medical Genetics (*Medisinsk Genetikk avdelingen*), Regional Teaching Hospital, Trondheim, Norway which ran local and national clinical laboratory services, including the first national routine service worldwide for clinical pharmacogenetics (1996-1998). The department also housed a SCIEX API 150 triple quadrupole mass spectrometer, the first TQMS in Norway.
 - (iv) Establishment, in collaboration with Dr. Frank J. Gonzalez, an internationally visible research group in metabolomics at the Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda (2004-). The group began with a single UPLC-ESI-QTOFMS funded by an award from the NCI director. We were successful in raising funds to purchase several more MS platforms, which now total nine. In this period, funding for radiation metabolomics was awarded to the lab from NIAID/NIH.
 - (v) The establishment in 1991 of the high impact pharmacology/toxicology/genetics journal *Pharmacogenetics*, later renamed *Pharmacogenetics and Genomics*, currently in its 31st year and volume.
 - (vi) The launch in 1992 of the campus-based biotechnology limited company GenoType Ltd., which rapidly became the world leader in the provision of genetic services to both the pharmaceutical industry in Europe, the USA and Japan, and US governmental research institutions. GenoType Ltd. was able to both raise venture capital and to develop patentable
- e5p

3. Professor Andrea De Gottardi, Gastroenterology and Hepatology, Ente Ospedaliero Cantonale, Lugano, Switzerland. Email: andrea.degottardi@insel.ch. Tel: +41 91 811 7637 [senior colleague and collaborator when in Bern].
4. Professor David Gordon, President, World Federation for Medical Education, 01210 Ferney-Voltaire, France. Email: president@wfme.org. Tel: +33 4 50 59 20 07 [contemporary and colleague at St Mary's Hospital Medical School, London].

12. Scientific publications

Over 430 original scientific articles, reviews, editorials and communications. Ranked in the **top 0.44%** in Pharmacology and Pharmacy (413/94,611) and in the **top 0.17%** of 230,678 worldwide researchers in oncology and carcinogenesis by Stanford University Top 2% Database (Ioannidis JPA, *et al. PLOS Biology* 2020; <https://doi.org/10.1371/journal.pbio.3000918>). Ranked in the **top 0.21%** of 114,350 worldwide published authors in metabolomics.

Complete publication list can be found at ORCID <http://orcid.org/0000-0002-6143-1520>

Total number of citations = 23,279; h-index = 84

287 Publications listed in PubMed; 284 in ORCID; 368 in Web of Science; 394 in Google Scholar
(

- Manna SK, Patterson AD, Yang Q, Krausz KW, Li H, Idle JR, Fornace AJ, Gonzalez FJ. Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse. *J Proteome Res* 2010; 9: 4176-4188.
- Li F, Patterson AD, Höfer CC, Krausz KW, Gonzalez FJ, Idle JR. Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics. *Biochem Pharmacol* 2010; 80: 1063-1074.

- London SJ, Daly AK, Cooper J, Carpenter CL, Ding L, Navidi WC, Idle JR. Lung cancer risk in relation to the CYP2E1 RsaI genetic polymorphism among African-Americans and Caucasians in Los Angeles County. *Pharmacogenetics* 1996, 6: 151-158.
- Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. *Pharmacogenetics* 1996, 6: 319-328.
- Cholerton S, Boustead C, Taber H, Arpanahi A, Idle JR. CYP2D6 genotypes in cigarette smokers and non-tobacco users. *Pharmacogenetics* 1996, 6: 261-263.
- Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. *Cancer Chemother Pharmacol* 1996; 38: 147-154.
- Boddy AV, English M, Pearson AD, Idle JR, Skinner R. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. *Eur J Cancer* 1996; 32A: 1179-1184.
- Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. *Ann Rheum Dis* 1996, 55: 66-68.
- Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. *Anals Rheumatol* 1996, 55: 66-68.
- Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson ADJ, Idle JR. Cyclophosphamide Metabolism in Children. *Cancer Res* 1995, 55: 803-809.
- Thomason JM, Seymour RA, Ellis JS, Kelly PJ, Parry G, Dark J, Idle JR. Iatrogenic gingival overgrowth in cardiac transplantation. *J Periodontol* 1995, 66: 742-746.
- Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen A-L, Idle JR, Gulbisanz MA, O'Grady D, O'Grady G. Iatrogenic gingival overgrowth in cardiac transplantation. *J Periodontol* 1995, 66: 742-746.
- Chin - J, Cpoebao NEA, (Chig Y-a) JTJ204159 0 TD0 Tc.0403 pgenotypes ina Jordansiac ppulation. I in *PharmacolTther* 1995, 8: 57425473.
- Cholerton

sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. *Am J Hum Genet* 1995, 57: 651-660.

Ellis JS, Seymour RA, Thomason JM, Butler TM, Idle JR. Periodontal variables affecting nifedipine sequestration in gingival crevicular fluid. *J Periodontol Res* 1995, 30: 272-276.

de Berker D, Ibbotson S, Simpson NB, Matthews JNS, Idle JR, Rees JL. Reduced experimental contact sensitivity in squamous cell but not basal cell carcinomas of the skin. *Lancet* 1995,

- Gregory WL, Mehal W, Dunn AN, Cavanagh G, Chapman R, Fleming KA, Daly AK, Idle JR, James OFW, Bassendine MF. Primary biliary cirrhosis: contribution of HLA class II allele DR8, *Quart J Med* 1993, 86: 393-399.
- Gregory WL, James OFW, Turner I, Meese CO, Idle JR. Re-evaluation of the metabolism of carbocysteine in a British white population: lack of evidence for a genetic polymorphism. *Pharmacogenetics* 1993, 3: 270-274.
- Foster JR, Idle JR, Hardwick JP, Bars R, Scott P, Braganza JM. Induction of drug-metabolizing enzymes in human pancreatic cancer and chronic pancreatitis. *J Pathol* 1993, 169: 457-463.
- Ellis JS, Seymour RA, Monkman S, Idle JR. Disposition of nifedipine in plasma and gingival crevicular fluid in relation to drug-induced gingival overgrowth. *J Periodontal Res* 1993; 28: 373-378.
- Ellis JS, Monkman SC, Seymour RA, Idle JR. Determination of nifedipine in gingival crevicular fluid: a capillary gas chromatographic method for nifedipine in microlitre volumes of biological fluid. *J Chromatogr B* 1993, 621: 95-101.
- Daly AK, Thomas DJ, Cooper J, Pearson WR, Neal DE, Idle JR. Homozygous deletion of the glutathione S-transferase M1 (GSTM1) gene is a risk factor in bladder cancer. *Brit Med J* 1993, 307: 481-482.
- Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. *Cancer Res* 1993, 53: 1-7.
- Armstrong MA, Idle JR, Daly AK. A polymorphic CfoI site in exon 6 of the human CYP2D6 gene detected by the polymerase chain reaction. *Human Genet* 1993, 91: 616-617.
- Tasso MJ, Boddy AV, Price L, Wyllie RA, Idle JR, Pearson ADJ. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. *Cancer Chemother Pharmacol* 1992, 30: 207-211.
- Philip PA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K, Carmichael J, Idle JR, Harris AL.

- Sardas S, Pontin J, Idle JR. Polymorphic 4-hydroxylation of debrisoquine in a Turkish population. *Pharmacogenetics* 1991; 1: 123-124.
- Nikolov IG, Chernozemsky IN, Idle JR. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor. *IARC Sci Pub* 1991; 115: 289-296.
- Daly, AK, Armstrong M, Monkman SC, Idle ME, Idle JR. The genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P450IID6) phenotypes. *Pharmacogenetics* 1991; 1: 33-41.
- Ayesh R, Dawling S, Hayler A, Oates NS, Choler

- Emery P, Panayi GS, Hutson G, Welsh KI, Mitchell SC, Shah RR, Idle JR, Smith RL, Waring RH. D-penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. *J Rheumatol* 1984; 11 626-632.
- Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. *Nature* 1984; 312:169-170.
- Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL. Genetically determined oxidation capacity and the disposition of debrisoquine. *Br J Clin Pharmacol* 1983; 15: 443-450.
- Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Prediction of subclinical perhexiline neuropathy in a patient with an inborn error of debrisoquine hydroxylation. *Am Heart J* 1983; 105: 159-161.
- Ritchie JC, Mitchell SC, Idle JR, Smith RL. Sex dimorphism of metiamide sulphoxidation and glucuronidation in rodent species. *Biochem Soc Trans* 1983; 11: 183-184.
- Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. *Clin Pharmacol Ther* 1983; 34: 827-834.
- Evans DAP, Harmer D, Downham DY, Whibley EJ, Idle JR, Ritchie J, Smith RL. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. *J Med Genet* 1983; 20: 321-329.
- Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. *Br J Clin Pharmacol* 1983; 16: 157-166.
- Waring RH, Mitchell SC, Shah RR, Idle JR, Smith RL. Polymorphic sulphoxidation of S-carboxymethyl-L-cysteine in man. *Biochem Pharmacol* 1982; 31: 3151-3154.
- Shah RR, Oates NS, Idle JR, Smith RL. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. *Br Med J* 1982; 284: 295-299.
- Osikowska BA, Idle JR, Swinbourne FJ, Sever PS. Unequivocal synthesis and characterisation of dopamine 3- and 4-O-sulphates. *Biochem Pharmacol* 1982; 31: 2279-2284.
- Oram M, Wilson K, Burnett D, Al-Dabbagh SG, Idle JR, Smith RL. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine. *Eur J Clin Pharmacol* 1982; 23: 147-150.
- Oates NS, Shah RR, Idle JR, Smith RL. Genetic polymorphism of phenformin 4-hydroxylation. *Clin Pharmacol Ther* 1982; 32 81-89.
- Nadir HH, Al-Dabbagh SG, Idle JR. Elevated serum cholesterol in drug-oxidation-deficient rats. *Biochem Pharmacol* 1982; 31: 81-89.
- Mitchell SC, Ritchie JC, Idle JR, Smith RL. Nature of the polar metabolites of metiamide and cimetidine in man. *Biochem Soc Trans* 1982; 10: 123-124.
- Mitchell SC, Idle JR, Smith RL. Reductive metabolism of cimetidine sulfoxide in man. *Drug Metab Dispos* 1982; 10: 289-290.
- Mitchell SC, Idle JR, Smith RL. The metabolism of [14C]cimetidine in man. *Xenobiotica* 1982; 12: 283-292.
- Küpfer A, Al-Dabbagh SG, Ritchie JC, Idle JR, Smith RL. Spectral binding studies of the polymorphically metabolised drugs debrisoquine, sparteine and phenformin by cytochrome P-450 by normal and hydroxylation deficient rat strains. *Biochem Pharmacol* 1982; 31: 3193-3199.
- Sloan TP, Idle JR, Smith RL. Influence of the DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. *Clin Pharmacol Ther* 1981; 29 493-497.

- Mitchell SC, Waring RH, Idle JR, Smith RL. Cimetidine pretreatment decreases carbocysteine sulphoxidation in man. *I.R.C.S. Med Sci* 1981; 9: 1028-1029.
- Idle JR, Mahgoub A, Sloan TP, Smith RL, Mbanefo CO, Bababunmi EA. Some observations of the oxidative phenotype status of Nigerian patients presenting with cancer. *Cancer Lett* 1981; 11: 331-338.
- Danhof M, Idle JR, Teunissen MWE, Sloan TP, Breimer DD, Smith RL. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. *Pharmacology* 1981; 22: 349-358.
- Al-Dabbagh SG, Idle JR, Smith RL. Animal modelling of human polymorphic drug oxidation - the metabolism of debrisoquine and phenacetin in rat inbred strains. *J Pharm Pharmacol* 1981; 33: 161-164.
- Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a British white population. *J Med Genet* 1980; 17: 102-105.
- Oates NS, Shah RR, Idle JR, Smith RL. On the urinary disposition of phenformin and 4-hydroxyphenformin and their rapid simultaneous measurement. *J Pharm Pharmacol* 1980; 32: 731-732.
- Mbanefo C, Bababunmi EA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. *Xenobiotica* 1980; 10: 811-818.
- Islam SI, Idle JR, Smith RL. The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. *Xenobiotica* 1980; 10: 819-825.
- Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL. Debrisoquine hydroxylation polymorphism among Ghanaians and caucasians. *Clin Pharmacol Ther* 1979; 26: 584-591.
- Wakile LA, Sloan TP, Idle JR, Smith RL. Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation. *J Pharm Pharmacol* 1979; 31: 350-352.
- Kitchen I, Tremblay J, Andre J, Dring LG, Idle JR, Smith RL, Williams RT. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxy-amphetamine. *Xenobiotica* 1979; 9: 397-404.
- Idle JR, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL. The metabolism of [14C]-debrisoquine in man. *Br J Clin Pharmacol* 1979; 7: 257-266.
- Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL. Polymorphism of carbon oxidation of drugs and clinical implications. *Br Med J* 1978; 2: 655-657.
- Mahgoub A, Idle JR, Smith RL. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. *Xenobiotica* 1978; 9: 51-56.
- Idle JR, Millburn P, Williams RT. Taurine conjugates as metabolites of arylacetic acids in the ferret. *Xenobiotica* 1978; 8: 253-264.
- Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylation phenotype. *Life Sci* 1978; 22: 979-984.
- Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. *Lancet* 1977; ii: 584-586 [citations 1,455].
- Hiron PC, Idle JR, Millburn P, Williams RT. Glutamine conjugation of phenylacetic acid in the ferret. *Biochem Soc Trans* 1977; 5: 1033-1035.
- Collins MW, French MR, Hiron PC, Idle JR, Bassir O, Williams RT. The conjugation of benzoic acid in the African bat *Epomops franqueti*. *Comp Biochem Physiol* 1977; 56C: 103-104.
- Angelo MM, Idle JR. The conjugation of benzoic acid and phenylacetic acid by the Pipestrelle bat. *Comp Biochem Physiol* 1977; 58C: 57-59.

- Idle JR, Millburn P, Williams RT, Zini G. The conjugation of arylacetic acids in the pigeon compared to the hen. *Biochem Soc Trans* 1976; 4: 141-143.
- Idle JR, Millburn P, Williams RT. Taurine conjugation of arylacetic acids in the ferret. *Biochem Soc Trans* 1976; 4: 139-141.
- Idle JR, Millburn P, Williams RT. Benzoylglutamic acid, a metabolite of benzoic acid in Indian fruit bats. *FEBS Lett* 1975; 59: 234-256.
- Caldwell J, French MR, Idle JR, Renwick AG, Bassir O, Williams RT. Conjugation of foreign compounds in the elephant and hyaena. *FEBS Lett* 1975; 60: 391-395.
- Bridges JW, Evans ME, Idle JR, Millburn P, Osiyemi FO, Smith RL, Williams RT. The conjugation of indolylic acid in man, monkeys and other species. *Xenobiotica* 1974; 4: 645-652.

B. Book chapters and review articles

- Beyo 4u D, Idle JR. The gut microbiota – a vehicle for the prevention and treatment of hepatocellular carcinoma. *Biochem Pharmacol*, in press.
- Beyo 4u D, Idle JR. Metabolic rewiring and the characterization of oncometabolites. *Cancers* 2021 June 10; 13(12):2900. doi: 10.3390/cancers13122900.
- Beyo 4u D, Idle JR. Metabolomic insights into the mode of action of natural products in the treatment of liver disease. *Biochem Pharmacol* 2020; 180: 114171.
- Beyo 4u D, Idle JR. Metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy. *Metabolites* 2020; 10: 50, 1-56; doi:10.3390/metabo10020050
- Beyo 4u D, Zhou Y, Chen C, Idle JR. Mass isotopomer-guided decluttering of metabolomic data to visualize endogenous biomarkers of drug toxicity. *Biochem Pharmacol* 2018; 156: 491-500.
- Beyo 4u D, Idle JR. A history and overview of phenotypic variability in CYP2D6 activity. In: *CYP2D6: Genetics, Pharmacology and Clinical Relevance* (Baumann P, Ed.), Future Medicine, London, 2014, p. 8-27.
- Beyo 4u D, Idle JR. Painting the liver with lasers: The future of liver histology? *Hepatology* 2013; 59: 757-760.
- Beyo 4u D, Idle JR. The metabolomic window into hepatobiliary disease. *J Hepatol* 2013; 59: 842-858.
- Beyo 4u D, Idle JR. Metabolomics and its potential in drug development. *Biochem Pharmacol* 2013; 85: 12-20.
- Beyo 4u D, Idle JR. The glycine deportation system and its pharmacological consequences. *Pharmacol Ther* 2012; 135: 151-167.
- Beyo 4u D, Smith RL, Idle JR. Dog bites man or man bites dog? The enigma of the amino acid conjugations. *Biochem Pharmacol* 2012; 83: 1331-1339.
- Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: Major impact on the metabolome. *Annu Rev Pharmacol Toxicol* 2012; 52: 37-56.
- Patterson AD, Gonzalez FJ, Idle JR. Xenobiotic metabolism in cancer research – A view through the metabolometer. *Chem Res Toxicol* 2010; 23: 851-860.
- Patterson AD, Lanz C, Gonzalez FJ,

- Idle JR, Hydroxylation phenotype and hepatocellular carcinoma. In: Drug Reactions and the Liver (M Davis, JM Treger and R Williams, eds) pp.313-315, Pitman Medical, London (1981).
- Ritchie JC, Sloan TP, Idle JR, Smith RL. Toxicological implications of polymorphic drug metabolism. In: Environmental Chemicals, Enzyme Function and Human Disease Ciba Foundation Symposium No. 76, pp.219-244 (1980).
- Idle JR, Smith RL. Inter-ethnic differences in the metabolic disposition of drugs and toxic substances. In: Toxicology in the Tropics (RL Smith and EA Bababunmi eds) pp 239-253, Taylor & Francis Ltd., London (1980).

- Tyburski J, Krausz K, Gonzalez F, Idle J. High-throughput, minimally invasive radiation biodosimetry in the mouse using metabolomics. NIH Research Festival, October 14-17, 2008, Abstract PHYSIO-10.
- Patterson A, Eichler G, Krausz K, Aslam S, Weinstein J, Hansen B, Idle J, Gonzalez F. Redefining the complex metabolic phenotype of type 2 diabetes by UPLC-ESI-TOFMS-based metabolomics profiling of rhesus macaque urine. NIH Research Festival, October 14-17, 2008, Abstract ENDO-5.
- Cheng J, Zhen YY, Krausz K, Idle J, Gonzalez F. Human CYP2D6-transgenic mouse. A model for the CYP2D6 polymorphism. NIH Research Festival, October 14-17, 2008, Abstract PHARM-2.
- Idle JR. From drug metabolism to drug metabolomics in mice. Prague Med Rep 2008; 109 Suppl: 49-50.
- Gonzalez FJ, Ma X, Yang Q, Idle JR. Humanized mouse models to predict chemical safety and metabolism. Proceedings of 236th ACS National Meeting & Exposition, Philadelphia, PA, USA, August 17-21, 2008.
- Ma X, Idle JR, Gonzalez FJ. Defining the role of pregnane X receptor in vivo using genetically engineered mouse models. Proceedings of the 17th International Symposium on Microsomes

inflammation and acute colitis. The Fellows Award for Research Excellence 2008 (FARE 2008), Poster #, NIH, September 25, 2007.
Tyburski JB, Slavík J, Krausz KW, Doiron K, Lanz C, Fornace AJ, Gonzalez FJ, Idle JR. Radiation

Holthe M, Klepstad P, Borchgrevink P, Kaasa S, Idle JR, Krokan HE, Skorpen F. The significance of the UGT2B7 His268Tyr polymorphism in the formation of morphine 3-glucuronide and morphine 6-glucuronide from morphine in humans. *Internat Na*

- Idle JR, Gonzalez FJ. Editorial, *Pharmacogenetics* 1992 2: 47.
- Idle JR, Gonzalez FJ. Editorial, *Pharmacogenetics* 1992 2: 1.
- Gregory W, Game F, Farrer M, Idle J, Laker M, James O. Lipoprotein(a)[Lp(a)] levels and primary biliary cirrhosis (PBC). British Hyperlipidaemia Association, July 1992, Cambridge.
- Daly AK, Armstrong M, Cholerton S, Bateman DN, Idle JR. CYP2D6 genotypes in Parkinson's disease. Abstract, 9th International Symposium on Microsomes and Drug Oxidations, Jerusalem, Israel, 1992.
- Tefre T, Daly A, Armstrong M, Haugen A, Idle J, Børresen A-L. Genotyping of the CYP2D6 gene in lung cancer patients and controls. Abstract, 9th International Symposium on Microsomes and Drug Oxidations, Jerusalem, Israel, 1992.
- Beyeler C, Armstrong M, Daly A, Idle JR, Astbury C, Bird HA, Debrisoquine (DBQ) oxidation polymorphisms do not predispose to rheumatoid arthritis (RA). *B J Rheumatol. Proc BSR Meeting*, 1992 31: 9.
- Beyeler C, Armstrong M, Daly A, Idle JR, Astbury C, Bird HA. Debrisoquine genotype as a marker of susceptibility to ankylosing spondylitis (AS). *B J Rheumatol, Proc BSR Meeting*, 1992 31: 7.
- Idle JR, Gonzalez FJ. Editorial, *Pharmacogenetics* 1992 1: 125.
- Idle JR, Gonzalez FJ. Editorial, *Pharmacogenetics* 1992 1: 65.
- Cholerton S, McCracken NW, Idle JR. Factors influencing individual variation in nicotine pharmacokinetics. Abstract, IUTOX Satellite Meeting on Absorption, Distribution, Metabolism and Excretion of Nicotine and Related Alkaloids, Salsomaggiore, Italy 1992.
- Boddy AV, Wyllie R, Price L, Pearson ADJ, Idle JR. Increased clearance of ifosfamide in children during continuous infusion or repeated bolus administration. Abstract, AAPS Annual Meeting November 15-19 1992, San Antonio, Texas, USA.
- Gregory W, Burke D, Robertson H, Wheeler J, Freeman R, Idle J, Bassendine M, James O. Plasma tumour necrosis factor a (TNF) inpatients with primary biliary cirrhosis. IASL, Brighton, June 1992.
- Gonzalez FJ, Idle JR. Pharmacogenetics - at the dawn of a new era. Abstract, Vth World Conference on Clinical Pharmacology & Therapeutics, Yokohama, Japan, 1992.
- Boddy, AV, Wyllie R, Price L, Idle JR, Pearson AJ. Pharmacokinetics and metabolism of ifosfamide in Paediatric patients. UKCCSG, November 1991, Oral Communication, accepted.
- Gregory WL, James OFW, Idle JR. Carbocysteine polymorphism and disease. *Lancet* 1992; 339: 616.
- Cholerton S, Idle M, Gonzalez FJ, Idle JR. A population study of coumarin

Küpfer A, Idle JR, Cerny T. Uroprotective activity of mesna in man and pH-dependent velocities of chloroacetaldehyde inactivation by thiol groups. Naun-Schm Arch Pharmacol, 1991; 344 Suppl. 1: R53

- Ayesh R, Al-Waiz M, Crothers MJ, Cholerton S, Mitchell SC, Idle JR, Smith RL. Deficient nicotine N-oxidation in two sisters with trimethylaminuria. *Br J Clin Pharmacol* 1988; 25: 664-665P.
- Weston A, Manchester DK, Choi JS, Rowe M, Trivers GE, Idle JR, Cartmel B, Vahakangas K, Mann DL, Harris CC. Detection and characterization of benzo[a]pyrene macromolecular adducts in human peripheral blood cells. *Proc Am Assoc Cancer Res* 1987; 28: 91.
- Oates NS, Ayesh R, Cartmel B, Idle JR. Influence of smoking on the distribution of the debrisoquine metabolic ratio. *Proc Xth Int Congr Pharmacol (Sydney)* 1987; Abstr P91.
- Elliot JM, Hardy JA, Hayes RJ, Idle JR. Phenotypic association between the effects of MPTP treatment and debrisoquine hydroxylation in the rat. *Br J Pharmacol* 1987; 91: 483P.
- Caporaso N, Hayes R, Dosemeci M, Hoover R, Idle J, Ayesh R. Debrisoquine metabolic phenotype (MP), asbestos exposure and lung cancer. *Proc Am Soc Clin Oncol* 1987; 6: 229.
- Brooks BA, Langley S, Jones SM, Oates NS, Idle JR, Hirom PC. Metabolism of benzo[a]pyrene in interleukin-2-dependent T-cells after benzanthracene treatment. *Proc 2nd Internat Workshop on P450 Gene Regulation (Airlie, Virginia)* 1987.
- Ayesh R, Oates NS, Hayler A, Widdop B, Idle JR, Smith RL. Influence of oxidation polymorphism on the pharmacokinetics of tricyclic antidepressants in man. *Br J Clin Pharmacol* 1987; 23: 645-646P.
- Al-Waiz M, Mitchell SC, Ayesh R, Idle JR, Smith RL. Variable N-oxidation of trimethylamine in man. *Br J Clin Pharmacol* 1987; 23: 614P.
- Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL. Trimethylaminuria [fish-odour syndrome]: an inborn error of oxidative metabolism. *Lancet* 1987; i: 634-645.
- Hayes RJ, Idle JR. The isolated vas deference of the whale: responses to electrical stimulation and drugs. *J Physiol* 1986; 374: 44P.
- Schmid B, Perry H, Feher M, Sever P, Idle J. Impaired metabolic dehydrogenation of nifedipine. *Acta Pharmacol Toxicol* 1986; Suppl V: 655.
- Perry H, Schmid B, Idle J. Dehydrogenation of nifedipine - fact and artifact. *Acta Pharmacol Toxicol* 1986; Suppl V: 485.
- Oates N, Crothers M, Shah R, Idle J, Smith R. Influence of dextropropoxyphene on oxidation phenotyping using debrisoquine and phenformin. *Acta Pharmacol Toxicol* 1986; Suppl V: 319.
- Idle J, Nadir H. Oxidation phenotype and urinary 20-hydroxy- and 17-oxo-steroid profiles. *Acta Pharmacol Toxicol* 1986; Suppl V: 314.
- Idle J, Hadidi H. Drug interactions with cyclophosphamide metabolism and disposition in mice. *Acta Pharmacol Toxicol* 1986; Suppl V: 1536.
- Hadidi H, Coulter C, Idle J. Cyclophosphamide "metabolic index" - a means of estimating metabolic activation of cyclophosphamide from urine. *Acta Pharmacol Toxicol* 1986; Suppl V: 1535.
- Feher M, Schmid B, Idle J, Sever P. Platelet aggregation and nifedipine plasma concentrations. *Acta Pharmacol Toxicol* 1986; Suppl V: 167.
- Crothers M, Cartmel B, Idle J. Chemical and biological stability of the debrisoquine metabolic ratio. *Acta Pharmacol Toxicol* 1986; Suppl V: 313.
- Cartmel B, Stockton M, Crothers M, Hadidi H, Idle J, Riordan J, McNicol M. Distribution of oxidation phenotypes in lung cancer families. *Acta Pharmacol Toxicol* 1986; Suppl V: 670.
- Al-Waiz M, Mitchell S, Idle J, Smith R. Variation of trimethylamine N-oxidation in man. *Acta Pharmacol Toxicol* 1986; Suppl V: 659.

- Idle JR. A novel role for taurine. In: Sulphur in Biology; Ciba Foundation Symposium, No. 72, pp. 282-284 (1980).
- Hetzel MR, Law M, Keal EE, Sloan TP, Idle JR, Smith RL. Is there a genetic component in bronchial carcinoma in smokers? *Thorax* 1980; 35: 709.
- Danhof M, Breimer D, Sloan TP, Idle JR, Smith RL. Antipyrine metabolite formation in extensive and poor hydroxylators of debrisoquine. *Proc 1st World Cong Clin Pharmacol (Wembley)* 1980.
- Chapman PH, Idle JR, Mahgoub A, Rawlins MD, Smith RL, Shuster S. Drug oxidation in psoriasis. *Br J Dermatol* 1980; 102: 728.
- Chapman PH, Idle JR, Mahgoub A, Mucklow JC, Rawlins MD, Rogers S, Shuster S, Smith RL. 4-Hydroxylation of debrisoquine in psoriasis. *Br J Clin Pharmacol* 1980; 9: 113-114P.
- Bababunmi EA, Idle JR, Mahgoub A, Mbanefo C, Smith RL. Polymorphic hydroxylation of debrisoquine in Nigerians. *Br J Clin Pharmacol* 1980; 9: 112-113P.
- Andoh B, Idle JR, Sloan TP, Smith RL, Woolhouse NM. Inter-ethnic and inter-phenotype differences among Ghanaians and caucasians in the metabolic hydroxylation of phenytoin. *Br J Clin Pharmacol* 1980; 9: 282-283P.
- Mutawa M, Islam SI, Idle JR, Drug oxidation in phenylketonuria. *Proc Conference on Paediatric Disease (Kuwait)* 1979.
- Mahgoub A, Idle JR, Smith RL. Genetically determined variability in drug 284 (1980)Mucklow JC, Raw